分子腫瘍学診断薬市場：製品、技術、がんタイプ、エンドユーザー別-2025-2030年の世界予測

分子腫瘍学診断薬市場は、2023年に88億4,000万米ドルと評価され、2024年には98億8,000万米ドルに達すると予測され、CAGR 11.83%で成長し、2030年には193億6,000万米ドルに達すると予測されています。

分子腫瘍学診断薬は、ゲノミクス、プロテオミクス、メタボロミクスなどの分子ベースの技術によるがんの検出と特徴づけに焦点を当てた、急速に発展している分野です。これらの診断の必要性は、早期発見、予後、治療成績を改善し、正確で個別化されたがん治療戦略の必要性に由来します。用途は、がんに関連する特定の遺伝子変異の特定から進行中の治療効果のモニタリングまで多岐にわたる。最終用途の範囲は病院、診断研究所、研究機関にまたがり、次世代シーケンシング（NGS）やポリメラーゼ連鎖反応（PCR）のような先進技術に依存しています。

市場の洞察によると、分子腫瘍学診断薬の成長を牽引しているのは、がん罹患率の増加、分子診断技術の進歩、精密医療に対する需要の高まりです。主要企業間の戦略的提携や合併も市場拡大を促進しています。費用対効果が高く、より利用しやすい診断ツールの開拓にチャンスがあり、ヘルスケアインフラが不十分な新興国市場を開拓できる可能性があります。診断プロセスにおけるAIと機械学習の統合は、悪性腫瘍を早期かつ正確に発見する有望な可能性を秘めています。しかし、高度な診断技術にかかるコストの高さ、データ解釈の複雑さ、迅速な市場参入を阻害する厳しい規制要件などの課題も残っています。

チャンスを生かすために、企業は非侵襲的リキッドバイオプシーの研究開発に注力し、特定のがん治療に対する患者の反応を予測できるコンパニオン診断の範囲を拡大すべきです。イノベーションの最良の分野としては、ポイントオブケア診断ソリューションの開発や、複雑ながんゲノムデータを効率的に解析するためのバイオインフォマティクスの強化が挙げられます。市場は競争的でありながらダイナミックであり、新規技術の採用と市場ポジションを強化するための戦略的提携の両方が重視されています。課題はあるもの、こうした制約を克服するために投資し、イノベーションを優先する企業が競争優位性を獲得し、分子腫瘍学診断薬市場の大幅な事業成長につながる可能性が高いです。

市場力学：急速に進化する分子腫瘍学診断薬市場の主要市場インサイトを公開

分子腫瘍学診断薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • がん患者の増加と高齢化
  • 自動化された高度な診断技術に対するニーズの高まり
  • 有利な医療費償還と個別化医療への動向
• 市場抑制要因
  • 分子腫瘍学診断薬検査に伴う高コスト
• 市場機会
  • がん診断薬の研究開発活動への継続的な投資
  • 分子生物学およびバイオテクノロジーにおける技術の進歩
• 市場の課題
  • 分子診断技術における一貫した基準の欠如と相まって、厳しい規制のハードル

ポーターのファイブフォース分子腫瘍学診断薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：分子腫瘍学診断薬市場における外部からの影響の把握

外部マクロ環境要因は、分子腫瘍学診断薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析分子腫瘍学診断薬市場における競合情勢の把握

分子腫瘍学診断薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス分子腫瘍学診断薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、分子腫瘍学診断薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨分子腫瘍学診断薬市場における成功への道筋を描く

分子腫瘍学診断薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がん罹患率の増加と人口の高齢化
    • 自動化された高度な診断技術に対するニーズの高まり
    • 医療費の有利な償還と個別化医療への傾向
  • 抑制要因
    • 分子腫瘍学診断薬テストに関連する高コスト
  • 機会
    • 腫瘍診断における研究開発活動への継続的な投資
    • 分子生物学とバイオテクノロジーにおける技術的進歩
  • 課題
    • 厳しい規制上のハードルと分子診断技術における一貫した基準の欠如
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 分子腫瘍学診断薬市場：製品別

• 機器
• 試薬

第7章 分子腫瘍学診断薬市場：技術別

• チップとマイクロアレイ
• インサイチューハイブリダイゼーション
• 等温核酸増幅技術（INAAT）
• 質量分析
• マルチプレックス
• PCR
• シーケンシング
• 転写による増幅

第8章 分子腫瘍学診断薬市場がんの種類別

• 血液がん
• 乳がん
• 子宮頸がん
• 大腸がん
• 腎臓がん
• 肝臓がん
• 肺がん
• 前立腺がん

第9章 分子腫瘍学診断薬市場：エンドユーザー別

• 診断センター
• 病院

第10章 南北アメリカの分子腫瘍学診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の分子腫瘍学診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの分子腫瘍学診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Agilent Technologies, Inc.
• Bayer AG
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Biocartis NV
• Biocept, Inc.
• BIOMERIEUX SA
• Danaher Corporation
• DiaSorin Molecular LLC
• Enzo Biochem, Inc.
• F. Hoffmann-La Roche Ltd.
• GenMark Saglik
• Hologic, Inc.
• Illumina, Inc.
• Leica Biosystems Nussloch GmbH
• Myriad Genetics, Inc.
• NeoGenomics Laboratories
• OncoCyte Corporation
• PathAI, Inc.
• Personal Genome Diagnostics Inc.
• QIAGEN N.V.
• Siemens AG
• Sysmex Asia Pacific Pte Ltd.
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CHIPS & MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT), BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY MULTIPLEX, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 44. CANADA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 45. CANADA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 46. CANADA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CANADA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 62. AUSTRALIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 63. AUSTRALIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 66. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 67. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 68. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 69. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 70. INDIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. INDIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 72. INDIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 73. INDIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 74. INDONESIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 75. INDONESIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 76. INDONESIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 77. INDONESIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 78. JAPAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. JAPAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 80. JAPAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 81. JAPAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 82. MALAYSIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 83. MALAYSIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 84. MALAYSIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 85. MALAYSIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 86. PHILIPPINES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 87. PHILIPPINES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 88. PHILIPPINES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 89. PHILIPPINES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 90. SINGAPORE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. SINGAPORE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 92. SINGAPORE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 93. SINGAPORE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 94. SOUTH KOREA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. SOUTH KOREA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 96. SOUTH KOREA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 97. SOUTH KOREA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 98. TAIWAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. TAIWAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 100. TAIWAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 101. TAIWAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 102. THAILAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 103. THAILAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 104. THAILAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 105. THAILAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 106. VIETNAM MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 107. VIETNAM MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 108. VIETNAM MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 109. VIETNAM MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 110. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 111. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 112. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 113. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 114. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 115. DENMARK MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 116. DENMARK MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 117. DENMARK MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 118. DENMARK MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 119. EGYPT MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 120. EGYPT MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 121. EGYPT MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 122. EGYPT MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 123. FINLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 124. FINLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 125. FINLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 126. FINLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 127. FRANCE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 128. FRANCE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 129. FRANCE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 130. FRANCE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 131. GERMANY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 132. GERMANY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 133. GERMANY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 134. GERMANY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 135. ISRAEL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 136. ISRAEL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 137. ISRAEL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 138. ISRAEL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 139. ITALY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 140. ITALY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 141. ITALY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 142. ITALY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 143. NETHERLANDS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 144. NETHERLANDS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 145. NETHERLANDS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 146. NETHERLANDS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 147. NIGERIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 148. NIGERIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 149. NIGERIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 150. NIGERIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 151. NORWAY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 152. NORWAY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 153. NORWAY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 154. NORWAY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 155. POLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 156. POLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 157. POLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 158. POLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 159. QATAR MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 160. QATAR MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 161. QATAR MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 162. QATAR MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 163. RUSSIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 164. RUSSIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 165. RUSSIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 166. RUSSIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 167. SAUDI ARABIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 168. SAUDI ARABIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 169. SAUDI ARABIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 170. SAUDI ARABIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 171. SOUTH AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 172. SOUTH AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 173. SOUTH AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 174. SOUTH AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 175. SPAIN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 176. SPAIN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 177. SPAIN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 178. SPAIN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 179. SWEDEN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 180. SWEDEN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 181. SWEDEN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 182. SWEDEN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 183. SWITZERLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 184. SWITZERLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 185. SWITZERLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 186. SWITZERLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 187. TURKEY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 188. TURKEY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 189. TURKEY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 190. TURKEY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 191. UNITED ARAB EMIRATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 192. UNITED ARAB EMIRATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 193. UNITED ARAB EMIRATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 194. UNITED ARAB EMIRATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 195. UNITED KINGDOM MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 196. UNITED KINGDOM MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 197. UNITED KINGDOM MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 198. UNITED KINGDOM MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 199. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 200. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Molecular Oncology Diagnostics Market was valued at USD 8.84 billion in 2023, expected to reach USD 9.88 billion in 2024, and is projected to grow at a CAGR of 11.83%, to USD 19.36 billion by 2030.

Molecular Oncology Diagnostics is a rapidly evolving field focused on the detection and characterization of cancer through molecular-based techniques, such as genomics, proteomics, and metabolomics. The necessity for these diagnostics stems from the need for precise and personalized cancer treatment strategies, improving early detection, prognosis, and therapeutic outcomes. Applications range from identifying specific genetic mutations associated with cancer to monitoring the effectiveness of ongoing treatments. The end-use scope spans across hospitals, diagnostic laboratories, and research institutes, relying on advanced technologies like next-generation sequencing (NGS) and polymerase chain reaction (PCR).

Market insights reveal that the growth of Molecular Oncology Diagnostics is driven by increased cancer prevalence, advancements in molecular diagnostics technology, and the rising demand for precision medicine. Strategic partnerships and mergers among key players are also fostering market expansion. Opportunities lie in developing cost-effective and more accessible diagnostic tools, which could tap into emerging markets with insufficient healthcare infrastructure. The integration of AI and machine learning in diagnostic processes holds promising potential for early and more accurate detection of malignancies. However, challenges persist, including the high costs of advanced diagnostic techniques, the complexity of data interpretation, and stringent regulatory requirements that can impede rapid market entry.

To capitalize on opportunities, companies should focus on R&D in non-invasive liquid biopsies and expand the scope of companion diagnostics that can predict patient responses to specific cancer treatments. Best areas of innovation include the development of point-of-care diagnostic solutions and the enhancement of bioinformatics to analyze complex cancerous genomic data efficiently. The market is competitive yet dynamic, emphasizing both the adoption of novel technologies and strategic collaborations to strengthen market position. Despite the challenges, companies that invest in overcoming these limitations and prioritize innovation are likely to gain a competitive advantage, leading to substantial business growth in the Molecular Oncology Diagnostics market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Molecular Oncology Diagnostics Market

The Molecular Oncology Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of cancer cases and aging population
  • Rising need for automated and advanced diagnostic techniques
  • Favorable health reimbursement and the trend toward personalized medicine
• Market Restraints
  • High cost associated with molecular oncology diagnostics test
• Market Opportunities
  • Ongoing investments in R&D activities in oncology diagnostics
  • Technological advancements in molecular biology and biotechnology
• Market Challenges
  • Stringent regulatory hurdles coupled with a lack of consistent standards in molecular diagnostic techniques

Porter's Five Forces: A Strategic Tool for Navigating the Molecular Oncology Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Molecular Oncology Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Molecular Oncology Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Molecular Oncology Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Molecular Oncology Diagnostics Market

A detailed market share analysis in the Molecular Oncology Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Molecular Oncology Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Molecular Oncology Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Molecular Oncology Diagnostics Market

A strategic analysis of the Molecular Oncology Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Molecular Oncology Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biocartis NV, Biocept, Inc., BIOMERIEUX SA, Danaher Corporation, DiaSorin Molecular LLC, Enzo Biochem, Inc., F. Hoffmann-La Roche Ltd., GenMark Saglik, Hologic, Inc., Illumina, Inc., Leica Biosystems Nussloch GmbH, Myriad Genetics, Inc., NeoGenomics Laboratories, OncoCyte Corporation, PathAI, Inc., Personal Genome Diagnostics Inc., QIAGEN N.V., Siemens AG, Sysmex Asia Pacific Pte Ltd., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Molecular Oncology Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Instruments and Reagents.
• Based on Technology, market is studied across Chips & Microarrays, In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology (INAAT), Mass Spectrometry, Multiplex, PCR, Sequencing, and Transcription Mediated Amplification.
• Based on Cancer Type, market is studied across Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, and Prostate Cancer.
• Based on End User, market is studied across Diagnostic Centers and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of cancer cases and aging population
    • 5.1.1.2. Rising need for automated and advanced diagnostic techniques
    • 5.1.1.3. Favorable health reimbursement and the trend toward personalized medicine
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with molecular oncology diagnostics test
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing investments in R&D activities in oncology diagnostics
    • 5.1.3.2. Technological advancements in molecular biology and biotechnology
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory hurdles coupled with a lack of consistent standards in molecular diagnostic techniques
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Molecular Oncology Diagnostics Market, by Product

• 6.1. Introduction
• 6.2. Instruments
• 6.3. Reagents

7. Molecular Oncology Diagnostics Market, by Technology

• 7.1. Introduction
• 7.2. Chips & Microarrays
• 7.3. In Situ Hybridization
• 7.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
• 7.5. Mass Spectrometry
• 7.6. Multiplex
• 7.7. PCR
• 7.8. Sequencing
• 7.9. Transcription Mediated Amplification

8. Molecular Oncology Diagnostics Market, by Cancer Type

• 8.1. Introduction
• 8.2. Blood Cancer
• 8.3. Breast Cancer
• 8.4. Cervical Cancer
• 8.5. Colorectal Cancer
• 8.6. Kidney Cancer
• 8.7. Liver Cancer
• 8.8. Lung Cancer
• 8.9. Prostate Cancer

9. Molecular Oncology Diagnostics Market, by End User

• 9.1. Introduction
• 9.2. Diagnostic Centers
• 9.3. Hospitals

10. Americas Molecular Oncology Diagnostics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Molecular Oncology Diagnostics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Molecular Oncology Diagnostics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Agilent Technologies, Inc.
• 3. Bayer AG
• 4. Becton, Dickinson and Company
• 5. Bio-Rad Laboratories, Inc.
• 6. Biocartis NV
• 7. Biocept, Inc.
• 8. BIOMERIEUX SA
• 9. Danaher Corporation
• 10. DiaSorin Molecular LLC
• 11. Enzo Biochem, Inc.
• 12. F. Hoffmann-La Roche Ltd.
• 13. GenMark Saglik
• 14. Hologic, Inc.
• 15. Illumina, Inc.
• 16. Leica Biosystems Nussloch GmbH
• 17. Myriad Genetics, Inc.
• 18. NeoGenomics Laboratories
• 19. OncoCyte Corporation
• 20. PathAI, Inc.
• 21. Personal Genome Diagnostics Inc.
• 22. QIAGEN N.V.
• 23. Siemens AG
• 24. Sysmex Asia Pacific Pte Ltd.
• 25. Thermo Fisher Scientific Inc.